GGrantIndex
← Leaderboards

Ottavio Arancio

Sloan-Kettering Inst Can Research

Google Scholar ↗PubMed ↗ORCID ↗
$29,644,569
Attributed
$41,122,089
Total exposure
21
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.3M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$41,122,089 · 21

By mechanism

R01$22,338,921 · 9
U01$9,410,435 · 3
RF1$4,500,013 · 2
P01$2,152,938 · 2
R56$1,892,729 · 3
R21$827,053 · 2

Top collaborators

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseSynapsesAmyloid Beta-ProteinFunctional DisorderBrainAffectPathway InteractionsMemoryNeuronsLong-Term PotentiationImpairmentMolecularProteinsSynaptic PlasticityIn VivoMouse ModelLaboratoriesBaseHippocampus (Brain)SliceLearningSynaptic FunctionComplex

Grant awards (79)

Chaperome networks in Alzheimer's disease$1,125,794
R01 · FY2025 · AG
Routes to Enhanced HIV Neuropathogenesis Through Expression of Subclinical Levels of Endogenous Amyloid-Beta$827,685
R01 · FY2025 · NS
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease$666,792
R01 · FY2025 · AG
Chaperome networks in Alzheimer's disease$1,165,073
R01 · FY2024 · AG
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease$680,400
R01 · FY2024 · AG
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,444,837
U01 · FY2023 · AG
Chaperome networks in Alzheimer's disease$1,183,214
R01 · FY2023 · AG
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease$680,400
R01 · FY2023 · AG
The Role of SUMOylation in Tau-Mediated Pathology$386,009
R01 · FY2023 · NS · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$329,000
U01 · FY2023 · AG
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta$2,475,013
RF1 · FY2022 · NS
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,516,817
U01 · FY2022 · AG
Chaperome networks in Alzheimer's disease$1,199,524
R01 · FY2022 · AG
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease$680,400
R01 · FY2022 · AG
The role of SUMOylation in Tau-mediated pathology$386,009
R01 · FY2022 · NS · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,472,881
U01 · FY2021 · AG
Chaperome networks in Alzheimer's disease$1,253,488
R01 · FY2021 · AG
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease$680,400
R01 · FY2021 · AG
The role of SUMOylation in Tau-mediated pathology$386,009
R01 · FY2021 · NS · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,475,773
U01 · FY2020 · AG
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta$868,544
R56 · FY2020 · NS
The role of SUMOylation in Tau-mediated pathology$380,398
R01 · FY2020 · NS · contact PI
Exploring the contribution of viral PP2A inhibition to tau pathology in Alzheimer's disease.$454,820
R21 · FY2019 · NS · contact PI
The role of SUMOylation in Tau-mediated pathology$425,562
R01 · FY2019 · NS · contact PI
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A$350,000
R01 · FY2019 · NS · contact PI
Extracellular tau oligomers and Alzheimer disease$328,000
R01 · FY2019 · AG · contact PI
The role of methylation-sensitive PP2A isoforms in regulating the pathological response to tau$2,025,000
RF1 · FY2018 · AG · contact PI
ECSIT protects against neurodegeneration and Alzheimer's disease through the regulation of mitochondrial function and oxidative stress$613,653
R56 · FY2018 · AG
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A$350,000
R01 · FY2018 · NS · contact PI
Extracellular tau oligomers and Alzheimer disease$328,000
R01 · FY2018 · AG · contact PI
On the role of microglia-derived extracellular vesicles in amyloid-beta induced changes in synaptic function and network activity.$410,532
R56 · FY2017 · AG · contact PI
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A$350,000
R01 · FY2017 · NS · contact PI
Extracellular tau oligomers and Alzheimer disease$328,000
R01 · FY2017 · AG · contact PI
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A$350,000
R01 · FY2016 · NS · contact PI
Extracellular tau oligomers and Alzheimer disease$328,000
R01 · FY2016 · AG · contact PI
SUMOylation and Amyloid-beta elevation$397,206
R01 · FY2015 · NS · contact PI
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2A$350,000
R01 · FY2015 · NS · contact PI
Extracellular tau oligomers and Alzheimer disease$328,000
R01 · FY2015 · AG · contact PI
SUMOylation and Amyloid-beta elevation$393,235
R01 · FY2014 · NS · contact PI
Endogenous amyloid-beta in synaptic function and memory$338,963
R01 · FY2014 · AG · contact PI
SUMOylation and Amyloid-beta elevation$383,306
R01 · FY2013 · NS · contact PI
Endogenous amyloid-beta in synaptic function and memory$321,776
R01 · FY2013 · AG · contact PI
Novel PDE5 inhibitors as a therapeutic tool against Alzheimer's Disease$317,630
U01 · FY2013 · AG · contact PI
SUMOylation and Amyloid-beta elevation$397,207
R01 · FY2012 · NS · contact PI
Novel PDE5 inhibitors as a therapeutic tool against Alzheimer's Disease$377,124
U01 · FY2012 · AG · contact PI
Endogenous amyloid-beta in synaptic function and memory$342,085
R01 · FY2012 · AG · contact PI
Calpain Inhibitors against Alzheimer's Disease$444,600
U01 · FY2011 · AG · contact PI
Novel PDE5 inhibitors as a therapeutic tool against Alzheimer's Disease$395,686
U01 · FY2011 · AG · contact PI
SUMOylation and Amyloid-beta elevation$372,487
R01 · FY2011 · NS · contact PI
Endogenous amyloid-beta in synaptic function and memory$343,722
R01 · FY2011 · AG · contact PI
Calpain Inhibitors against Alzheimer's Disease$562,537
U01 · FY2010 · AG · contact PI
Endogenous amyloid-beta in synaptic function and memory$369,903
R01 · FY2010 · AG · contact PI
ABAD AND AB-INDUCED CELL STRESS AND SYNAPTIC$290,505
P01 · FY2010 · AG · contact PI
CORE--BEHAVIOR AND NEUROPATHOLOGY$157,328
P01 · FY2010 · AG · contact PI
Calpain Inhibitors against Alzheimer's Disease$33,468
U01 · FY2010 · AG · contact PI
Calpain Inhibitors against Alzheimer's Disease$553,477
U01 · FY2009 · AG · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$412,874
R01 · FY2009 · NS · contact PI
ABAD AND AB-INDUCED CELL STRESS AND SYNAPTIC$299,815
P01 · FY2009 · AG · contact PI
CORE--BEHAVIOR AND NEUROPATHOLOGY$154,279
P01 · FY2009 · AG · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$31,470
R01 · FY2009 · NS · contact PI
Calpain Inhibitors against Alzheimer's Disease$486,605
U01 · FY2008 · AG · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$405,421
R01 · FY2008 · NS · contact PI
ABAD AND AB-INDUCED CELL STRESS AND SYNAPTIC$281,543
P01 · FY2008 · AG · contact PI
NO/cGMP/CREB pathway enhancers for treatment of Alzheimer's Disease$201,170
R21 · FY2008 · AG · contact PI
CORE--BEHAVIOR AND NEUROPATHOLOGY$149,796
P01 · FY2008 · AG · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$42,461
R01 · FY2008 · NS · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$404,317
R01 · FY2007 · NS · contact PI
ABAD AND AB-INDUCED CELL STRESS AND SYNAPTIC$255,069
P01 · FY2007 · AG · contact PI
NO/cGMP/CREB pathway enhancers for treatment of Alzheimer's Disease$171,063
R21 · FY2007 · AG · contact PI
CORE--BEHAVIOR AND NEUROPATHOLOGY$148,393
P01 · FY2007 · AG · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$412,494
R01 · FY2006 · NS · contact PI
ABAD AND AB-INDUCED CELL STRESS AND SYNAPTIC$274,156
P01 · FY2006 · AG · contact PI
CORE--BEHAVIOR AND NEUROPATHOLOGY$142,054
P01 · FY2006 · AG · contact PI
Mechanisms of Synaptic Dysfunction by Amyloid Peptides$423,331
R01 · FY2005 · NS
Role of Presynaptic Proteins in Transmitter Release$286,125
R01 · FY2004 · NS
Role of Presynaptic Proteins in Transmitter Release$153,475
R01 · FY2003 · NS
Role of Presynaptic Proteins in Transmitter Release$104,121
R01 · FY2003 · NS
Role of Presynaptic Proteins in Transmitter Release$254,420
R01 · FY2002 · NS
Role of Presynaptic Proteins in Transmitter Release$251,365
R01 · FY2001 · NS